FOR IMMEDIATE RELEASE NEWS RELEASE Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization -- Company also reports preliminary unaudited 2024 revenue of $701.0 million -- Parsippany, NJ., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced its five-year growth-oriented plan to accelerate ...

EXHIBIT 2.1 Execution version and AKOYA BIOSCIENCES, INC. Dated as of January 9, 2025 TABLE OF CONTENTS | ARTICLE 1 DEFINITIONS | | 2 | | --- | --- | --- | | 1.01 | Definitions | 2 | | 1.02 | Other Definitional Provisions | 15 | | | ARTICLE 2 THE MERGER | 16 | | 2.01 | Shares of Merger Sub | 16 | | 2.02 | The Merger | 16 | | 2.03 | Closing | 17 | | 2.04 | Effective Time | 17 | | 2.05 | Effects of the Merger | 17 | | 2.06 | Certificate of Incorporation and Bylaws | 17 | | 2.07 | Directors and Officers of the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2025 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation) 25 Mall Road, Suite 203 Burlington, Massachusetts 01803 (Address of principal executive offices) (Zip Code) (Commission File Number) Delaware 001-38293 4 ...

M=>7>I ))475-1)55216-17)562)/-8)4#2/70)4296,-5'-3/-1)(4-'-1+'6-215%1( ((-6-21%/256 %8-1+5$,-/)4-8-1+1'4)0)16%/%4.)6-1+18)560)165 203%1;)67415126,)4<- -//-2162 ,%4),2/()45-1 ,%4))374',%5)5 $,-/)216-17-1+62(8%1')42%()4-5'-3/-1)(%3-6%///2'%6-214-24-6-)5 "3(%6)5-5'%/ 76/22.$-6,)(7')(4296,:3)'6%6-215 *24)6 %/)5%1(3)4%6-1+ 1'20)2*16)434-5)%1(75-1)55)529)45)3246)( %1(29)41(2*203%4%&/) 7-(%1')1'4)%5)53)4%6-1+%5,/29%1(4))%5,/29!%4+)65 | | | | | 9?JHI:9 6GC>CAJI:9):I$C8DB: 'DHH+:G.=6G: | | --- | --- | --- | --- | --- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39272 E2open Parent Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 86-1874570 (State or other ...

Exhibit 99.1 ROYALTY PHARMA TO HIGHLIGHT ACCOMPLISHMENTS AND PROVIDE BUSINESS UPDATE AT 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE NEW YORK, NY, January 10, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments, and the full year 2024 outlook for Portfolio Receipts. Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer, will discuss these updates on January 14, 2025 as part of a webcast presentation to be held a ...

Exhibit 99.1 www.e2open.com Press Release E2open Announces Fiscal 2025 Third Quarter Financial Results GAAP subscription revenue of $132.0 million, above midpoint of Q3 guidance range DALLAS – January 10, 2025 – E2open Parent Holdings, Inc. (NYSE: ETWO) ("e2open" or the "Company"), the connected supply chain SaaS platform with the largest multi-enterprise network, today announced financial results for its fiscal third quarter ended November 30, 2024. "During the third quarter, e2open made further progress i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14063 JABIL INC. (Exact name of registrant as specified in its charter) Delaware 38-1886260 (State or other jurisdiction of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2025 INTELLIA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37766 36-4785571 (State or Other Jurisdiction of Incorporation) 40 Erie Street, Suite 130 Cambridge, Massachusetts 02139 (Address of Principal Executive Offices) (Zip Code) (Commissio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K 1375 West Fulton Street, Suite 1300 Chicago, Illinois 60607 (Address of principal executive offices, including zip code) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation) Delaware 001-40880 87-10 ...